Biocompatibility of Heparin-Coated Circuits Used in Cardiopulmonary Bypass

References

• Antonsen S, Brandslund I, Clemensen S, Sofeldt S, Madsen T, Alstrup P. Neutrophil lysosomal enzyme release and complement activation during cardiopulmonary bypass. Scand J Thor Cardiovasc Surg 1987; 21: 47–52
   PubMed Web of Science ®Google Scholar
• Berntzen H B., Munthe E, Fagerhol M K. A longitudinal study of leucocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis. J Rheumatol 1989; 16: 1416–1420
   PubMed Web of Science ®Google Scholar
• Borowiec J, Bylock A, van der Linden J, Thelin S. Heparin-coating reduces blood cell adhesion to arterial filters during coronary bypass—a clinical study. Ann Thorac Surg 1993; 55: 1540–1545
   PubMedGoogle Scholar
• Borowiec J, Thelin S, Bagge L, Hultman J, Hansson H-E. Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose. Scand J Thor Cardiovasc Surg 1992; 26: 177–185
   PubMed Web of Science ®Google Scholar
• Borowiec J, Thelin S, Bagge L, Nilsson L, Venge P, Hansson H E. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass—a clinical study. J Thorac Cardiovasc Surg 1992; 104: 642–647
   PubMedGoogle Scholar
• Butler J, Rocker G M., Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 552–559
   PubMed Web of Science ®Google Scholar
• Colman R W. Platelet activation in cardio-pulmonary bypass. Ann Thorc Surg 1990; 49: 32–34
   PubMed Web of Science ®Google Scholar
• Colton T. Statistics in medicine, 1st ed. Little, Brown and Co., Boston 1974; 207–214
   Google Scholar
• de Palma L, Yu M, McIntosh C L., Swain J A., Davey R J. Changes in lymphocyte subpopulations as a result of cardiopulmonary bypass. The effect of blood transfusion J Thorac Cardiovasc Surg 1991; 101: 240–244
   PubMedGoogle Scholar
• Edens R E., Linhardt R J., Weiler J M. Heparin is not just an anticoagulant anymore: six and one-half decades of studies on the ability of heparin to regulate complement activity. Complement today, J M. Cruse, R H. Lewis. Karger, Basel 1993; 96–120
   Google Scholar
• Garred P, Fosse E, Fagerhol M K., Videm V, Mollnes T E. Calprotectin and complement activation during major operations with or without cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 694–699
   PubMedGoogle Scholar
• Gu Y J., van Oeveren W, Akkerman C, Boonstra P W., Huyzen R J., Wildevuur C RH. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 917–922
   PubMed Web of Science ®Google Scholar
• Hammerschmidt D E., Stroncek D F., Bowers T K., Lammi-Keefe C J., Kurth D M., Ozalins A, Nicoloff D M., Lillehei R C., Craddock P R., Jacob H S. Complement activation and neutropenia occuring during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981; 81: 370–377
   PubMed Web of Science ®Google Scholar
• Kirklin J K., Westaby S, Blackstone E H., Kirklin J W., Chenoweth D E., Pacifico A D. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86: 845–857
   PubMed Web of Science ®Google Scholar
• Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a reducing terminal residue. Biomat Med Devices Artif Organs 1983; 11: 161–174
   PubMed Web of Science ®Google Scholar
• Larsson R, Larm O, Olsson P. The search for thromboresistance using immobilized heparin. Ann NY Acad Sci 1987; 516: 102–115
   PubMed Web of Science ®Google Scholar
• Lohrer R M., Trammer A R., Dietrich W, Hagl S, Linderkamp O. The influence of extracorporeal circulation and hemoseparation on red cell deformability and membrane proteins in coronary artery disease. J Thorac Cardiovasc Surg 1990; 99: 735–740
   PubMedGoogle Scholar
• Mancini G, Carbonara A O., Hermans J F. Immunochemical quantification of antigens by single radial immunodiffusion. Immunochemistry 1965; 2: 235–254
   PubMedGoogle Scholar
• Mollnes T E., Lea T, Froland S S., Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunoadsorbent assay based on monoclonal antibodies against neoantigen on the complex. Scand J Immunol 1985; 22: 197–202
   PubMed Web of Science ®Google Scholar
• Nilsson Ekdahl K, Nilsson B, Pekna M, Nilsson U R. Generation of iC3 at the interface between blood and gas. Scand J Immunol 1992; 35: 85–91
   PubMed Web of Science ®Google Scholar
• Nilsson L, Storm K-E, Thelin S, Bagge L, Hultman J, Thorelius J, Nilsson U. Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. Artif Organs 1990; 14: 46–48
   PubMedGoogle Scholar
• Nilsson U R.O.L., Nilsson B, Storm K-E, Elwing H, Nilsson Ekdahl K. Modification of the complement binding properties of polystyrene: effects of end-point heparin attachment. Scand J Immunol 1993; 37: 349–354
   PubMedGoogle Scholar
• Oeveren Wv, Wildevuur C RH, Kazatchkine M D. Biocompatibility of extracorporeal circuits in heart surgery. Transfus Sci 1990; 11: 5–33
   PubMedGoogle Scholar
• Olofsson T, Olsson I, Venge P, Elgefors B. Serum myeloperoxidase and lactoferrin in neutropenia. Scand J Haematol 1977; 18: 113–120
   PubMedGoogle Scholar
• Pekna M, Hagman L, Halden E, Nilsson U R., Nilsson B, Thelin S. Complement activation during cardiopulmonary bypass: effects of immobilized heparin in a clinical study. Ann Thorac Surg 1993, in press
   Google Scholar
• Pekna M, Larsson R, Formgren B, Nilsson U R., Nilsson B. Complement activation by polymethyl methacrylate (PMMA) minimized by end-point heparin attachment. Biomaterials. 1993; 14: 189–192
   PubMed Web of Science ®Google Scholar
• Reseth A G., Fagerhol M K., Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodological study. Scand J Gastroenterol 1992; 27: 793–798
   PubMedGoogle Scholar
• Sander J, Fagerhol M K., Bakken J S., Dale I. Plasma levels of leukocyte L1 protein in febrile conditions: relation to aetiology, number of leukocytes in blood, blood sedimentation reaction and C-reactive protein. Scand J Clin Lab Invest 1984; 44: 357–362
   PubMed Web of Science ®Google Scholar
• Semb A G., Gabrielsen T O., Halstensen T S., Fagerhol M K., Brandtzaeg P, Vaage J. Cardiac surgery and distribution of the leukocyte L1 protein-calprotectin. Eur J Cardiothorac Surg 1991; 5: 363–367
   PubMedGoogle Scholar
• Videm V, Svennevig J L., Fosse E, Semb G, Osterlund A, Mollnes T E. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992; 103: 806–813
   PubMed Web of Science ®Google Scholar
• von Segesser L K., Weiss B M., Garcia E, Gallino A, Turina M. Reduced blood loss and transfusion requirements with low systemic heparinization: preliminary clinical results in coronary artery revascularization. Eur J Cardiothorac Surg 1990; 4: 639–643
   PubMed Web of Science ®Google Scholar